Japan · Delayed Price · Currency is JPY RaQualia Pharma Statistics
Total Valuation
RaQualia Pharma has a market cap or net worth of JPY 13.38 billion. The enterprise value is 11.67 billion.
| Market Cap | 13.38B |
| Enterprise Value | 11.67B |
Important Dates
The last earnings date was Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RaQualia Pharma has 26.03 million shares outstanding. The number of shares has increased by 15.12% in one year.
| Current Share Class | 26.03M |
| Shares Outstanding | 26.03M |
| Shares Change (YoY) | +15.12% |
| Shares Change (QoQ) | -1.50% |
| Owned by Insiders (%) | 12.51% |
| Owned by Institutions (%) | -3.83% |
| Float | 17.41M |
Valuation Ratios
The trailing PE ratio is 240.20.
| PE Ratio | 240.20 |
| Forward PE | n/a |
| PS Ratio | 3.51 |
| PB Ratio | 1.65 |
| P/TBV Ratio | 3.02 |
| P/FCF Ratio | 97.07 |
| P/OCF Ratio | 65.78 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.49, with an EV/FCF ratio of 84.68.
| EV / Earnings | 219.34 |
| EV / Sales | 3.06 |
| EV / EBITDA | 16.49 |
| EV / EBIT | 50.99 |
| EV / FCF | 84.68 |
Financial Position
The company has a current ratio of 6.16, with a Debt / Equity ratio of 0.34.
| Current Ratio | 6.16 |
| Quick Ratio | 5.44 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 3.93 |
| Debt / FCF | 20.21 |
| Interest Coverage | 3.85 |
Financial Efficiency
Return on equity (ROE) is 0.78% and return on invested capital (ROIC) is 0.76%.
| Return on Equity (ROE) | 0.78% |
| Return on Assets (ROA) | 1.37% |
| Return on Invested Capital (ROIC) | 0.76% |
| Return on Capital Employed (ROCE) | 2.21% |
| Weighted Average Cost of Capital (WACC) | 7.57% |
| Revenue Per Employee | 44.88M |
| Profits Per Employee | 626,059 |
| Employee Count | 85 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 4.04 |
Taxes
In the past 12 months, RaQualia Pharma has paid 195.57 million in taxes.
| Income Tax | 195.57M |
| Effective Tax Rate | 78.61% |
Stock Price Statistics
The stock price has decreased by -19.06% in the last 52 weeks. The beta is 0.87, so RaQualia Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -19.06% |
| 50-Day Moving Average | 740.90 |
| 200-Day Moving Average | 783.97 |
| Relative Strength Index (RSI) | 23.12 |
| Average Volume (20 Days) | 328,590 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RaQualia Pharma had revenue of JPY 3.81 billion and earned 53.22 million in profits. Earnings per share was 2.14.
| Revenue | 3.81B |
| Gross Profit | 3.14B |
| Operating Income | 228.89M |
| Pretax Income | 248.78M |
| Net Income | 53.22M |
| EBITDA | 708.04M |
| EBIT | 228.89M |
| Earnings Per Share (EPS) | 2.14 |
Balance Sheet
The company has 4.49 billion in cash and 2.79 billion in debt, with a net cash position of 1.71 billion or 65.61 per share.
| Cash & Cash Equivalents | 4.49B |
| Total Debt | 2.79B |
| Net Cash | 1.71B |
| Net Cash Per Share | 65.61 |
| Equity (Book Value) | 8.09B |
| Book Value Per Share | 316.65 |
| Working Capital | 5.43B |
Cash Flow
In the last 12 months, operating cash flow was 203.40 million and capital expenditures -65.56 million, giving a free cash flow of 137.84 million.
| Operating Cash Flow | 203.40M |
| Capital Expenditures | -65.56M |
| Depreciation & Amortization | 479.15M |
| Net Borrowing | -493.77M |
| Free Cash Flow | 137.84M |
| FCF Per Share | 5.30 |
Margins
Gross margin is 82.42%, with operating and profit margins of 6.00% and 1.40%.
| Gross Margin | 82.42% |
| Operating Margin | 6.00% |
| Pretax Margin | 6.52% |
| Profit Margin | 1.40% |
| EBITDA Margin | 18.56% |
| EBIT Margin | 6.00% |
| FCF Margin | 3.61% |
Dividends & Yields
RaQualia Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.12% |
| Shareholder Yield | -15.12% |
| Earnings Yield | 0.40% |
| FCF Yield | 1.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RaQualia Pharma has an Altman Z-Score of 4.09 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.09 |
| Piotroski F-Score | 8 |